6 min

Geneva, 22 May 2025 – During a ceremony organized under the auspices of the African Union andthe World Health Organization (WHO) and on the sidelines of the 78th World Health Assembly inGeneva, representatives from six African countries – Chad, Djibouti, Ethiopia, Somalia, South Sudan, and Sudan– signed a Memorandum of Understanding (MoU) aimed at eliminating visceralleishmaniasis, one of the deadliest neglected diseases. During the event, the six African signatory countries were joined by Cameroon, Niger, Nigeria, Senegal, and Tanzania to call for improved cross-border cooperation and concrete collaborativeactions to tackle other neglected tropical diseases (NTDs).

Visceral leishmaniasis, also known as kala-azar, is one of the deadliest parasitic killers after malaria. It causes fever, extreme fatigue, weight loss, spleen and liver enlargement, and death if left untreated. Over 70% of the global burden is in the Eastern African region, where half of the affected people are children under 15.NTDs in general affect more than 1 billion people each year and disproportionately impact already vulnerable and impoverished communities. However, significant progress has been made over the past decade: As of May 2025, 56 countries have eliminated at least one NTD globally, including Togo(four NTDs) and Benin, Ghana, and India (three NTDs).

In 2024 and 2025, several other African countries achieved this target for one or two NTDs: most recently, Mauritania, Chad, Guinea, andNiger were acknowledged by WHO for eliminating an NTD.‘As the global community reaches the half-way point towards the roadmap targets and almost one year after we launched a strategic framework for the elimination of visceral leishmaniasis, the criticalrole of country-led efforts and cross-border collaboration in accelerating elimination cannot be overemphasized,’ said Dr Ibrahima Socé Fall, Director of the WHO Global Neglected Tropical Diseases Program in his opening remarks.

The signatories of the MoU agreed to invest resources, develop effective strategies at the regional level, and collaborate closely to achieve the targets outlined in the visceral leishmaniasis elimination framework launched by Eastern African countries in June 2024 . During the event organized in Geneva, Ministers of Health from Cameroon, Niger, and Nigeria alsoissued a ‘Call for Action’ to eliminate NTDs in general and were joined by their fellow Ministers whowere present.‘We know that diseases do not stop at borders — and neither should our response.

More than 600 million people on our continent remain at risk of at least one of the neglected tropical diseases,’ said Dr. Jean Kaseya, Director General of Africa CDC, in a statement read by Dr Landry Tsague Dongmo, Director of Africa CDC’s Center for Primary Health Care.‘Africa CDC has been working to enhance cross-border surveillance platforms through the Integrated Disease Surveillance and Response framework, in close collaboration with the WHO, he added.

Animals transmit many NTDs, and their spread is facilitated by factors such as climate
change and population movements; the interconnected nature of these diseases means that
Cooperation is essential to tackling them. The Call for Action, therefore, urges endemic countries to
work closely together on region-specific strategies, share information and data with their
neighbours, and jointly plan and implement health policies.
‘Visceral leishmaniasis patients and their communities urgently need new, improved oral treatments.
To reach elimination, we need more medical innovation. The recent successes of South Asian
countries, such as Bangladesh, in eliminating kala-azar show that global elimination of this dreadful
disease is within our reach, and I would like to commend the inspiring leadership, unity, and

commitment shown today by our African partners,’ said Dr Luis Pizarro, Executive Director of the non-
Profit medical research organization, Drugs for Neglected Diseases Initiative (DNDi).

The African Union Commission, the Global Onchocerciasis Network spearheaded the event for Elimination (GONE), and the WHO, the END Fund, and DNDi supported it.
ENDS.
About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization
that discovers, develops, and delivers safe, effective, and affordable treatments for neglected
populations. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river
blindness, mycetoma, dengue, paediatric HIV, cryptococcal meningitis, and hepatitis C. Its research
priorities include children’s health, gender equity and gender-responsive R&D, and diseases
impacted by climate change. Since its creation in 2003, DNDi has collaborated with public and private
partners worldwide to deliver twelve new treatments for six deadly diseases, saving millions of lives.
dndi.org